Disrupting key pathways in the network can drive AIS escape, providing insight into tumor development and targeted therapy resistance mechanisms, which can potentially be harnessed to reinstate senescence or drive PI3K/AKT/mTORC1-driven cancers toward death. The gene discussed is AKT1; the disease is cancer.